

July 5, 2014



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 10822-review.doc).

**Title:** Cost-effectiveness analysis of colon cancer treatment from MOSIAC and No.16968 trials

**Author:** Feng Wen, Ke Yao, Ze-Dong Du, Xiao-Feng He, Peng-Fei Zhang, Rui-Lei Tang, Qiu Li

**Name of Journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO:** 10822

The manuscript has been improved according to the suggestions of reviewers:

1 Format has been updated

2 Revision has been made according to the suggestions of the reviewer

(1) To the specific comment 1: "The INTRODUCTION part is too long and could be more precise. E.g. which protocol is the standard in an adjuvant therapy of colon, and only colon, not colorectal cancer."

According to the comment, we have shorted the INTRODUCTION part of our manuscript, and deleted some detail information about MOSIAC and No.16968 trials, which are about adjuvant therapy of colon cancer. As a result, the introduction began with colorectal cancer, then came to the main topic colon cancer, [seeing page 5 in the revised manuscript](#).

(2) To the specific comment 2: "The presentation of literature in the text is inadequate. The presentation of literature should correspond to the guidelines of the journal and if said in the text e.g.: ..... after lung and breast cancer(Siegel et al., 2013)..... Better: according to Siegel et al. [1]....."

According to the guideline of BPG's revision policies for research report, we revised the literature presentation with the help of NPG language editing.

(3) To the specific comment 3: "It will be also of benefit not to mention the Duke's Classification any more, therefore the UICC or AJCC- classification."

I could not agree more on this. As a result, we have deleted the Duke's Classification on [page 5 in the revised manuscript](#).

(4) To the specific comment 4: "In the INTRODUCTION part it is said that: "... adjuvant FOLFOX is a cost-effective treatment for stage II or III colon cancer compared..." adjuvant therapy is indicated in stage III (UICC/ AJCC) colon cancer. The basis of data for the treatment of stage II (UICC/AJCC) is poor."

This is a meaningful question, which we have considered twice when we wrote the manuscript. According to the NCCN Guideline version 2.2014, adjuvant chemotherapy is needed for stage II (UICC/AJCC) colon patients with high-risk factors, which were poorly differentiated histology(exclusive of those cancers that are MSI-H), lymphatic/vascular invasion, bowel obstruction, <12 lymph nodes examined, perineural invasion, localized perforation, or close, indereterminate, or positive margins.


However, about 60% analyzed patients in MOSIAC trial and all the patients in N0.16968 trial were in stage III. As a result we excluded the patients in stage II, and only included the patient in stage III ([seeing](#)

page 6 in the revised manuscript).

3 References and typesetting were corrected

Thank you again for publishing our manuscript in the *World Journal of Gastroenterology*.

Sincerely yours,

A handwritten signature in black ink, appearing to read 'Qiu Li', is positioned above the printed name.

Qiu Li, MD, PhD

Dept. of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy

West China Hospital, Sichuan University

No.37 Guoxuexiang, Chengdu

610041-China

Fax: +86-28-85423609

E-mail: fbqiu9@163.com